Department of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Gdansk University of Technology, Gdansk, Poland.
Drug Metab Dispos. 2012 Sep;40(9):1736-43. doi: 10.1124/dmd.112.045401. Epub 2012 Jun 1.
5-Diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311 (NSC-645809), is an antitumor agent shown to be effective against breast cancer in phase II clinical trials. A similar compound, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305, shows high activity against experimental tumors and is expected to have even more beneficial pharmacological properties than C-1311. Previously published studies showed that these compounds are not substrates for cytochrome P450s; however, they do contain functional groups that are common targets for glucuronidation. Therefore, the aim of this work was to identify the human UDP-glucuronosyltransferases (UGTs) able to glucuronidate these two compounds. High-performance liquid chromatography analysis was used to examine the activities of human recombinant UGT1A and UGT2B isoforms and microsomes from human liver [human liver microsomes (HLM)], whole human intestinal mucosa [human intestinal microsomes (HIM)], and seven isolated segments of human gastrointestinal tract. Recombinant extrahepatic UGT1A10 glucuronidated 8-hydroxyl groups with the highest catalytic efficiency compared with other recombinant UGTs, V(max)/K(m) = 27.2 and 8.8 μl · min⁻¹ · mg protein⁻¹, for C-1305 and C-1311, respectively. In human hepatic and intestinal microsomes (HLM and HIM, respectively), high variability in UGT activities was observed among donors and for different regions of intestinal tract. However, both compounds underwent UGT-mediated metabolism to 8-O-glucuronides by microsomes from both sources with comparable efficiency; V(max)/K(m) values were from 4.0 to 5.5 μl · min⁻¹ · mg protein⁻¹. In summary, these studies suggest that imid azoacridinone and triazoloacridinone drugs are glucuronidated in human liver and intestine in vivo and may form the basis for future translational studies of the potential role of UGTs in resistance to these drugs.
5-二乙氨基乙基氨基-8-羟基咪唑并[4,5-h]喹啉酮,C-1311(NSC-645809),是一种在 II 期临床试验中被证明对乳腺癌有效的抗肿瘤药物。一种类似的化合物,5-二甲基氨基丙基氨基-8-羟基三唑并[4,5-h]喹啉酮,C-1305,对实验性肿瘤显示出高活性,预计比 C-1311 具有更有益的药理学特性。先前的研究表明,这些化合物不是细胞色素 P450s 的底物;然而,它们确实含有常见的葡萄糖醛酸化靶标功能基团。因此,这项工作的目的是鉴定能够葡萄糖醛酸化这两种化合物的人 UDP-葡糖醛酸基转移酶(UGTs)。高效液相色谱分析用于检测人重组 UGT1A 和 UGT2B 同工型以及人肝微粒体[人肝微粒体(HLM)]、全人肠黏膜[人肠微粒体(HIM)]和人胃肠道七个分离段的活性。重组肝外 UGT1A10 对 8-羟基的葡萄糖醛酸化催化效率最高,与其他重组 UGT 相比,V(max)/K(m)分别为 27.2 和 8.8 μl·min⁻¹·mg 蛋白⁻¹,用于 C-1305 和 C-1311。在人肝和肠微粒体(HLM 和 HIM)中,供体之间和肠道不同区域的 UGT 活性存在高度变异性。然而,两种化合物都经历了 UGT 介导的代谢,生成 8-O-葡萄糖醛酸酯,来自两种来源的微粒体的效率相当;V(max)/K(m)值为 4.0 至 5.5 μl·min⁻¹·mg 蛋白⁻¹。总之,这些研究表明,咪唑并[4,5-h]喹啉酮和三唑并[4,5-h]喹啉酮类药物在人肝和肠内体内被葡萄糖醛酸化,可能为未来研究 UGT 在这些药物耐药性中的潜在作用奠定基础。